NCT04512716
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
StatusActive, Not Recruiting
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 28 versions: 20 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 28 words
- Enrollment closed, study ongoing
- Enrollment target: estimated 12 to confirmed 11
- Site details revised at 7 of 7 sites
- Notable Primary and study completion dates: Jan 2026 to Jan 2027v26
- Notable Enrollment target: 6 to 12v25
- Study Identification, Study Status, Oversight, Contacts/Locationsv24
- Study Identification, Study Status, Oversightv23
Show 14 earlier versionsHide 14 earlier versions
- Notable Primary and study completion dates: Jan 2025 to Jan 2026v22
- Study Identification, Study Status, Oversightv21
- Minor Collaborators shortened, about 2 wordsv15
- Notable Primary and study completion dates: Jan 2024 to Jan 2025
- Study sites: 1 to 7
- Eligibility criteria shortened, about 1 word
- Notable Eligibility criteria expanded, about 44 wordsv13
- Notable Primary and study completion dates: Jan 2023 to Jan 2024v12
- Notable Eligibility criteria expanded, about 144 wordsv10
- Notable Primary and study completion dates: Jan 2022 to Jan 2023v9
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria expanded, about 6 words
- Start date changed from estimate of Feb 2021 to Feb 2, 2021
- Site details revised
- Minor Start date: Jan 2021 to Feb 2021v6
- Notable Start date: Oct 2020 to Jan 2021
- Primary and study completion dates: Aug 2021 to Jan 2022
- Minor Start date: Sep 2020 to Oct 2020v4
- Notable Eligibility criteria expanded, about 2 words
- Start date: Aug 31, 2020 to Sep 2020
- Minor Study title shortened, about 1 wordv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Dose-limiting toxicities and maximum tolerated dose of 131-I apamistamab, when given in combination with 19-28z CAR T-cells for treatment of relapsed or refractory B-cell ALL or DLBCL
Timeframe: 30 days after treatment
Arms and interventions
B-Cell Acute Lymphoblastic Leukemia/Diffuse Large B-Cell LymExperimental
Participants will have relapsed or refractory B-Cell Acute Lymphoblastic Leukemia or Diffused Large B-Cell Lymphoma
Drugs: 131-I Apamistamab
Biologicals: CAR T-cell
Sites
7 sites in 1 country